US Stock Futures Flat Ahead Of Durable-Goods Orders Data
US stock futures traded mostly flat in early pre-market trade. Data on durable goods orders for February will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average gained 1 point to 17,950.00, while the Standard & Poor's 500 index futures rose 1.15 points to 2,086.15. Futures for the Nasdaq 100 index gained 4.40 points to 4,433.40.
A Peek Into Global Markets
European markets were lower today, with the Spanish Ibex Index dropping 0.38%, STOXX Europe 600 Index falling 0.44% and German DAX 30 index dropping 0.47%. French CAC 40 Index slipped 0.63% and London's FTSE 100 Index fell 0.06%.
In Asian markets, Japan's Nikkei Stock Average gained 0.17%, Hong Kong's Hang Seng Index climbed 0.53%, China's Shanghai Composite Index slipped 0.83% and India's BSE Sensex slipped 0.18%.
Analysts at CLSA downgraded Tesla Motors (NASDAQ: TSLA) from Outperform to Underperform.
Tesla shares fell 1.84% to $198.00 in pre-market trading.
- VBL Therapeutics (NASDAQ: VBLT) today announced top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM), which demonstrated a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin(R)) upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone upon disease progression (p=0.05). To read the full news, click here.
- WABCO (NYSE: WBC) signed a long-term supply agreement with Hendrickson Trailer Commercial Vehicle Systems to provide an advanced air disc brake (ADB) system for trailers in North America. To read the full news, click here.
- Samsung SDI and ABB (NYSE: ABB) have signed a memorandum of understanding to establish a strategic commercial alliance. Samsung SDI and ABB join forces to develop and market microgrid systems that comprise energy storage solutions. To read the full news, click here.
- Avalanche Biotechnologies (NASDAQ: AAVL) today announced that it has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop products based on Avalanche's proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), commonly known as red-green color blindness. To read the full news, click here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.